Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation

被引:70
作者
Brigger, I
Chaminade, P
Marsaud, V
Appel, M
Besnard, M
Gurny, R
Renoir, M
Couvreur, P
机构
[1] Univ Paris Sud 11, Fac Pharm, UMR 8612, F-92296 Chatenay Malabry, France
[2] Univ Geneva, Sch Pharm, CH-1211 Geneva 4, Switzerland
关键词
nanospheres; near infrared hydrophilic/hydrophobic model; poly(MePEGeyanoacrylate-co-hexadecylcyanoacrylate); tamoxifen; transcription inhibitory activity;
D O I
10.1016/S0378-5173(00)00628-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
When dealing with solid tumors in vivo, pegylated long-circulating carrier systems show, after intravenous administration. an attractive extravasation profile with an enhanced localization in the tumoral interstitium. These systems could be of help fur the delivery of cancer fighting drugs, such as Tamoxifen, a well known antiestrogen used in breast cancer therapy that possesses an extended biodistribution in vivo. This work aimed at encapsulating Tamoxifen in long-circulating poly(MePEGcyanoacrylate-co-hexadecylcyanoacrylate) 1:4 nanospheres. Tamoxifen-loaded poly( MePEGcyanoacrylate-co-hexadecylcyanoacrylate) nanospheres were successfully synthesized and characterized in terms of hydrophilicity/hydrophobicity by a model made up From near infrared spectra using principal component analysis. Zeta potential, drug loading, encapsulation efficiency, as well as biological effect, in vitro release and nanospheres integrity were also investigated. Even though near infrared spectroscopy could not detect Tamoxifen, it revealed that Pluronic F68 was associated with the pegylated nanospheres. HPLC measurements demonstrated that Tamoxifen was encapsulated in the pegylated nanospheres following a partition equilibrium between the polymeric and the aqueous phases. The Tamoxifen encapsulated in the nanospheres still showed a transcription inhibitory activity in ex vivo experiments. However, zeta potential and in vitro release suggested that Tamoxifen was essentially localized at the nanoparticles surface, resulting in an important and immediate drug release. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:37 / 42
页数:6
相关论文
共 10 条
  • [1] BRIGGER I, IN PRESS PHARM RES
  • [2] Chaminade P, 1998, ANALUSIS, V26, pM33
  • [3] DEMIRPENCE E, 1993, J STEROID BIOCHEM, V46, P335
  • [4] LIPOSOME CIRCULATION TIME AND TUMOR TARGETING - IMPLICATIONS FOR CANCER-CHEMOTHERAPY
    GABIZON, AA
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1995, 16 (2-3) : 285 - 294
  • [5] MacGregor JI, 1998, PHARMACOL REV, V50, P151
  • [6] Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate hexadecyl cyanoacrylate amphiphilic copolymer
    Peracchia, MT
    Vauthier, C
    Desmaële, D
    Gulik, A
    Dedieu, JC
    Demoy, M
    d'Angelo, J
    Couvreur, P
    [J]. PHARMACEUTICAL RESEARCH, 1998, 15 (04) : 550 - 556
  • [7] Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting
    Peracchia, MT
    Fattal, E
    Desmaële, D
    Besnard, M
    Noël, JP
    Gomis, JM
    Appel, M
    d'Angelo, J
    Couvreur, P
    [J]. JOURNAL OF CONTROLLED RELEASE, 1999, 60 (01) : 121 - 128
  • [8] SEYMOUR LW, 1992, CRIT REV THER DRUG, V9, P135
  • [9] SURFACE MODIFICATION OF NANOPARTICLES TO OPPOSE UPTAKE BY THE MONONUCLEAR PHAGOCYTE SYSTEM
    STORM, G
    BELLIOT, SO
    DAEMEN, T
    LASIC, DD
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1995, 17 (01) : 31 - 48
  • [10] *WAT CORP, 1996, WATERS COLUMN, V6, P6